Evidence map›Paper›PMID 31898311›Full record

ArticleJournal of endocrinological investigation2020

Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors?

S Martínez-López, A García-Martínez, M E Torregrosa-Quesada, B López-Muñoz, R Cámara, C Fajardo, C Lamas, A Picó

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

S Martínez-LópezResearch Laboratory, Alicante General University Hospital-ISABIAL, Alicante, Spain.
A García-MartínezResearch Laboratory, Alicante General University Hospital-ISABIAL, Alicante, Spain.
M E Torregrosa-QuesadaBiochemical Analysis Department, Alicante General University Hospital, Alicante, Spain.
B López-MuñozEndocrinology Department, Alicante General University Hospital, Alicante, Spain.
R CámaraEndocrinology Department, La Fe Polytechnic and University Hospital, Valencia, Spain.
C FajardoEndocrinology Department, La Ribera University Hospital, Alzira, Valencia, Spain.
C LamasEndocrinology Department, Albacete University Hospital Complex, Albacete, Spain.
A PicóEndocrinology Department, Alicante General University Hospital-ISABIAL, Miguel Hernández University, Calle Pintor Baeza, 12, 03010, Alicante, Spain. antonio.pico@umh.es.
Hospital General Universitario de Alicante Doctor Balmis · ESHospital de La Ribera · ESHospital Universitari i Politècnic La Fe · ESUniversitat de Miguel Hernández d'Elx · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silent somatotroph tumors (sSTs) are pituitary neuroendocrine tumors (PitNETs) which do not give rise to the clinical syndrome of acromegaly. Differently to their functioning counterparts, the adjuvant medical treatment with somatostatin analogues (SSAs) or dopamine receptors agonists (DAs) has been scarcely addressed in these tumors. As preliminary results of an ongoing research on silencing mechanisms involved in the pathogenesis of sSTs, we have characterized by qRT-PCR the expression of SSTRs and DRDs in a large series of 18 silent and 68 functioning STs. Although the expression of SSTR2 and SSTR5 was lower in sSTs than in functioning ones, we found a negative correlation between SSTR2 and the tumor size of the sSTs. Additionally, levels of expression of DRD2 were similar between the two subtypes suggesting a possible basis for the treatment of these tumors with SSAs and DAs.

Indexed as

AdenomaAdultBiomarkers, TumorDisease ManagementFemaleGene Expression ProfilingHumansMaleMiddle AgedNeuroendocrine TumorsPituitary NeoplasmsReceptors, Dopamine D2Receptors, SomatostatinSomatotrophsBiomarkers, TumorDRD2 protein, humanReceptors, Dopamine D2Receptors, SomatostatinSSTR2 protein, humanAcromegalyDopamine receptor (DRD)Pituitary neuroendocrine tumor (PitNET)Silent somatotroph tumor (sST)Somatostatin analogues (SSAs)Somatostatin receptor (SSTR)

Identifiers

PMID31898311
OpenAlexW2998706006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.